# US 12,178,826 B2 · Formulations for the delivery of autophagy stimulating trehalose

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,178,826 B2
- Document ID: US12178826B2
- Status: Granted
- Kind: B2
- Application number: 18/109,568
- Filed: 2023-02-14
- Published: 2023-09-07
- Granted: 2024-12-31
- Earliest claimed: 2017-08-08
- Applicants: Robert John Petcavich
- Inventors: Robert John Petcavich
- Web page: https://patentgrep.com/patent/US12178826B2

## CPC

- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A pharmaceutically acceptable composition comprising trehalose and a pharmaceutically acceptable excipient and methods of delivering autophagy stimulating trehalose to a patient in need thereof.

## Claims

### Claim 1

A method of delivering autophagy stimulating therapeutics to a patient in need thereof comprising the step of administering a pharmaceutically acceptable composition consisting of trehalose or a pharmaceutically-acceptable salt thereof and a pharmaceutically acceptable excipient and/or carrier.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said patient suffers from cardiovascular, liver or neurodegenerative disease.

### Claim 3 (depends on 2)

The method according to claim 2, wherein said patient suffers from a neurodegenerative disease selected from the group consisting of cardiovascular atherosclerosis, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis and Alzheimer's disease.

### Claim 4 (depends on 3)

The method according to claim 3, wherein said patient receives a dose ranging from 1 to 1000 milligrams.

### Claim 5 (depends on 4)

The method according to claim 4, wherein said dose is between 25 to 150 milligrams.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said patient receives a dose ranging from 1 to 5000 milligrams.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said dose is between 50 to 500 milligrams.

### Claim 8 (depends on 1)

The method according to claim 1, further comprising the step of administering an enhancing agent.

### Claim 9 (depends on 8)

The method according to claim 8, wherein said enhancing agent is selected from the group consisting of rapamycin, metformin, pharmaceutically-acceptable salts thereof and any combination thereof.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said trehalose or a pharmaceutically-acceptable salt thereof is delivered as an aerosol.